#VisualAbstract: Adjuvant pembrolizumab does not reduce health-related quality of life in patients with stage III melanoma
Click to read the study in The Lancet Oncology. Click to see previously reported survival outcomes from the same cohort.
Click to read the study in The Lancet Oncology. Click to see previously reported survival outcomes from the same cohort.
Click to read the study in The Lancet Oncology.
Click to read the study in JAMA Oncology.
Click to read the study in the European Journal of Cancer.
Click to read the study in the European Journal of Cancer.
Click to read the study in Melanoma Research.
Click to read the study in The Lancet Oncology.
Click to read the study in the European Journal of Cancer.
Click to read the study in the European Journal of Cancer.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.